GlassScriptPhysician profile
Kathleen Q Lutter
NPI 1588764799
$1,618.41
in general payments reported to CMS, 2019-2025
22 companies · $737 in 2025
The $737 reported for 2025 was more than what 87% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $165 · 2024: $716 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,502 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,501.66 |
| Education | $116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $182.60 | 2023-2025 | Injectafer |
| Astellas Pharma US INC | $169.39 | 2024-2025 | Veozah |
| Amgen INC. | $155.56 | 2023-2025 | Evenity, Prolia, Prolia |
| Pacira Pharmaceuticals Incorporated | $147.11 | 2024-2025 | Exparel, Iovera, Zilretta |
| Mayne Pharma Commercial LLC | $130.78 | 2023-2025 | |
| Abbvie INC. | $120.48 | 2023-2025 | |
| Millicent US INC | $110.20 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Coopersurgical, INC. | $78.22 | 2024-2025 | Paragard T 380a |
| Biogen, INC. | $71.10 | 2024-2025 | Zurzuvae |
| Shield Therapeutics INC | $68.82 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $64.28 | 2024-2025 | Myfembree |
| Myriad Women'S Health, INC. | $59.18 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $58.72 | 2024-2025 | |
| Exeltis, USA INC. | $43.07 | 2023-2024 | Slynd |
| Pfizer INC. | $40.29 | 2024 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $34.35 | 2024-2025 | Nexplanon |
| Exact Sciences Corporation | $21.73 | 2025 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $17.23 | 2024 | Bd Onclarity |
| Agile Therapeutics, INC. | $16.61 | 2024 | Twirla |
| Alexion Pharmaceuticals, INC. | $14.36 | 2025 | Ultomiris |
| Aspira Women'S Health INC | $14.33 | 2024 | Ova1 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Lutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.